Real world clinical experience with a new formulation of levothyroxine engineered to meet new and stricter regulatory requirements

A new LT4 formulation (Euthyrox [LT4 NF]) was developed to meet new regulatory standards, and has replaced the older formulation (LT4 OF) in a number of countries. We evaluated the possibility of tolerability/safety concerns associated with the switch by analysing spontaneous adverse event (AE) reports before and after switching.We examined spontaneous reports of adverse events (AE) from 18 countries generated from individual case safety reports...